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The panel addressed four main areas of
vaccine development and use: diseases of public
health importance for which no vaccine is
available; diseases for which an existing licensed
vaccine is not optimal and alternative vaccines
are under development; diseases for which a
vaccine exists but is not being used optimally; and
diseases requiring vaccines of specialized or
limited use, such as those needed for controlling
outbreaks or for military use. The specific
diseases chosen to illustrate each area were
malaria, influenza, meningitis, and filovirus
infections (Ebola and Marburg), respectively.
Lee Hall, National Institute of Allergy and
Infectious Diseases, addressed the basic chal-
lenges in developing a malaria vaccine. The
historical norm of vaccine development has been
an empirical process; in contrast, modern
vaccines take advantage of basic knowledge of the
organism and of the immune response to it. In
vaccine development, certain elements are
prerequisite: demonstrable protective immunity
and intimate knowledge of the organism’s life
cycle, including the DNA sequence. Vaccine
development has three potential goals: prevent
infection, prevent disease, and prevent transmis-
sion. A successful vaccine may address any or all
these areas; for malaria, a vaccine able to perform
any of these would have a significant impact.
Vaccine development, often thought of as a flow, is
in fact an iterative process; it addresses scientific,
technical, manufacturing, and clinical issues and is
affected by economic, political, and social issues
usually outside the scientific sphere of influence.
Several downstream gaps in vaccine development
include resource limitation, lack of standardization,
and problems in clinical and industrial interest.
Claude Hannoun, Institut Pasteur, ad-
dressed problems in influenza vaccine develop-
ment. Influenza, the quintessential emerging
infectious disease, needs a new vaccine each year
to protect against the predominant strains. The
disease poses additional challenges; one is the
need for vaccine against a potential pandemic
strain, particularly a pandemic strain whose
epidemiologic characteristics are different from
those of usual strains (e.g., the 1918 strain killed
young adults). Vaccine production problems pose
another challenge. Identifying an appropriate
seed strain can delay initiation of production for 4
to 6 months after the need for a vaccine has been
identified, and growing sufficient quantities of
vaccine is difficult. The issue of an appropriate
vaccine regimen (one dose or two) was also
addressed. The many vaccination issues involved
in a pandemic situation make the adoption of a
credible pandemic plan imperative. The emer-
gence of the H5N1 strain in Hong Kong has
underlined this imperative.
Brad Perkins, Centers for Disease Control
and Prevention, presented the challenge of the
African meningitis belt, where periodic large
epidemics affect approximately 1% of the
population with a 10% death rate. Since the
current vaccine does not confer lasting protection,
prediction of these epidemics can trigger vaccina-
tion campaigns to prevent deaths. A model using an
epidemic threshold of 15 cases per 100,000
demonstrated potential lives saved. Obstacles to
the use of the vaccine include inadequate
surveillance, high cost of the vaccine, inadequate
delivery systems, and inadequate vaccine supply.
Vaccines for agents such as Marburg and
Ebola were discussed by Alan Schmaljohn, U.S.
Army Medical Research Institute of Infectious
Diseases. Limited-use vaccines do not have a
global market but are potentially important
against the threat of biological weapons or
epidemics. These vaccines have unique problems,
such as inadequate efficacy testing (since there is
no disease-endemic area) and high production
costs (since there is no target population).
All the presentations addressed public policy
issues: who will use the vaccine and under what
circumstances, what is the time frame for
vaccine development (short-term versus long-
term), what is the cost of a vaccine (who bears
the brunt of development costs), how are these
costs recouped, and what is the role of
partnerships in determining vaccine need and
use.
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